---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-019803"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:19:11.167004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M

## Summary
- Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.
- Ketamine market currently $750M, projected to reach $3.35B globally by 2034.
- Plans citizen petition to remove benzethonium chloride from all IV ketamine products.
- Complements ongoing NDA for suicidal depression; PDUFA target late 2025; FDA waived $4.3M fee.
- Patent protection sought through 2045; Fast Track designation previously granted.

## SEC filing metadata
- accession: 0001437749-25-019803
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/0001437749-25-019803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/nrxp20250607_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-019803
- JSON: https://secwatch.observer/filing/0001437749-25-019803.json
- Plain text: https://secwatch.observer/filing/0001437749-25-019803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.